Foghorn Therapeutics Inc. (FHTX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Investors who purchased Foghorn securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Foghorn has violated federal securities laws.
On April 24, 2023, Foghorn issued a press release “announc[ing] an update on the FHD-609 program in synovial sarcoma and SMARCB1-deleted tumors.” The press release stated that “Foghorn is pausing enrollment in the FHD-609 study in synovial sarcoma and SMARCB1-deleted tumors due to a grade 4 QTc prolongation event in a synovial sarcoma patient at the second highest dose. Enrollment of the dose escalation portion of the study has been completed and a maximum tolerated dose has been identified. Patients in the affected cohort were dose reduced and additional safety measures have been discussed with and provided to the study investigators. The Company promptly communicated the enrollment pause and risk mitigation actions to the FDA and European regulatory authorities. Consequently, the FDA placed the study on partial clinical hold in the United States, while allowing patients currently enrolled and benefiting from therapy to continue dosing and to remain on FHD-609. The Company is not at this time planning to pursue a dose expansion study independently.” On this news, Foghorn’s stock price fell sharply during intraday trading on April 24, 2023.
If you are aware of any facts relating to this investigation or purchased Foghorn shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.